Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Sep 13, 2024 · Conclusions Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small …
Immunotherapy Success Rate for Lung Cancer: What Patients …
4 days ago · Learn the immunotherapy success rate for lung cancer, who benefits most, and what clinical studies show about survival, response, and long-term outcomes.
Perioperative durvalumab plus chemotherapy plus new agents …
May 31, 2025 · In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive …
Durvalumab Alone or Combined With Agents for ... - JAMA Network
Jul 15, 2025 · This randomized clinical trial reports the objective response rate, progression-free survival, overall survival, and safety profile of durvalumab plus oleclumab and durvalumab plus …
Lung Cancer Immunotherapy Drug Names – Complete Guide
Dec 16, 2024 · Each cancer type has unique traits and demands specific care plans. Non-Small Cell Lung Cancer (NSCLC) Non-small cell lung cancer is the most common type, making up …
Durvalumab Receives FDA Approval for Treatment of Non-Small Cell Lung ...
Aug 16, 2024 · Durvalumab (Imfinzi; AstratZeneca) in combination with chemotherapy has been approved by the FDA for the treatment of adult patients with resectable early (IIA-IIIB) non …
FDA Expands Durvalumab Label to Operable Lung Cancer
Aug 16, 2024 · The FDA expanded the labeling of the immunotherapy durvalumab (Imfinzi) on Thursday to include the perioperative treatment of resectable non-small cell lung cancer …
Early-Stage Non–Small Cell Lung Cancer - KEYTRUDA
KEYTRUDA can be used as part of a treatment plan that may help prevent early-stage NSCLC from coming back after surgery KEYTRUDA may be used in combination with chemotherapy …
5 Key Oncology FDA Approvals From November | AJMC
4 days ago · November saw numerous FDA approvals across the health care continuum, including several in oncology. These approvals cover treatments for hematologic cancers, non …
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Oct 23, 2023 · Lung cancer is the leading cause of cancer-related death worldwide, with non–small-cell lung cancer (NSCLC) accounting for over 80% of cases. 1-3 Approximately 25 …